GlycoVaxyn AG

GlycoVaxyn utilized its biological conjugation platform to develop next-generation bioconjugate vaccines against bacterial infections. GlycoVaxyn and GSK launched a research collaboration in December 2012 at which point GSK also entered as minority shareholder. In February 2015 GSK acquired remaining shares of GlycoVaxyn for 190 MUSD resulting in a total valuation of the company at 212 MUSD. LimmaTech Biologics AG was founded as a spin-off of GlycoVaxyn after the acquisition and is developing vaccines exclusively for GSK. The team remained in Schlieren after the acquisition as of 2017.